CJC-1295 with DAC: healthy-adult study regimens
> Updated:
Calculate the CJC-1295 with DAC dose
The calculator is already set up for CJC-1295 with DAC — adjust the dose or diluent volume for your vial.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 1 mg (1000 mcg) subcutaneously, once weekly | Starting dose |
| Maintenance | 2 mg once weekly | Increase if needed |
| Split regimen | 2 mg per week, divided into 2 injections (1 mg each) | Maximum in this schedule |
A full review of the mechanism and clinical data is available in the monograph.
Practical dosage and effect notes
In a study by Teichman and colleagues (Journal of Clinical Endocrinology & Metabolism, 2006), healthy adults aged 21–61 received CJC-1295 subcutaneously in two trials: in the first, a single injection at one of four ascending doses (30, 60, 125 or 250 mcg/kg); in the second, 2 injections 2 weeks apart (30 or 60 mcg/kg) or 3 weekly injections (20 or 30 mcg/kg). Depending on dose, growth hormone levels rose 2- to 10-fold and stayed elevated for at least 6 days, while IGF-I rose 1.5- to 3-fold and stayed elevated for 9–11 days after just one injection; the authors rated CJC-1295 relatively well tolerated, particularly at 30 or 60 mcg/kg: at higher doses, injection-site reactions tended to be more severe or longer-lasting.
That directly explains why the schedule on this page describes once-weekly dosing rather than daily: if a single shot's effect lasts up to 11 days, a weekly interval sustains the level, and the authors considered a minimum dosing interval of 7 days reasonable. The effect does build up, though: in the multiple-dose trial, peak IGF-I was higher after each subsequent injection, particularly with injections every 7 days. The split regimen (2 mg weekly as two 1 mg injections) is a practical option for anyone uncomfortable with one larger volume, not a change in pharmacokinetics.
This is background for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 5 mg vial.CJC-1295 with DAC5 mg+ 2 mlDiluent
- 2Get the concentrationExample: 5 mg in 2 ml =CJC-1295 with DAC2.5 mg/ml(2,500 mcg/ml)
- 3Work out the volume per doseFor example, for a 1 mg dose:1 mg = 0.4 ml= 40 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
CJC-1295 with DAC: reference regimens
CJC-1295 with DAC is given subcutaneously; albumin binding extends its half-life to ~6–8 days, so regimens are described as once-weekly dosing.
People search CJC-1295 DAC dosing mostly to understand why the schedule is once weekly instead of daily like most growth-hormone research peptides.
More scientific background in the CJC-1295 with DAC monograph
Notes and safety
- • CJC-1295 with DAC is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
